Clinical trial · Interventional
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
Beta-glucan's Immuno-modulatory Effect on Non-Small Cell Lung Cancer
NCT00682032CI-TRIAL-00084548recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine how beta-glucan affects the immune system in subjects with non-small cell lung cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| beta-glucan | Dietary Supplement | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- AIM 2: subjects with suspected or definitive NSCLC diagnosis
- description
- 1 (one) 250mg beta-glucan capsule 3 times a day for 14 days
- interventionNames
- Dietary Supplement: beta-glucan
- type
- EXPERIMENTAL
- label
- AIM 3: subjects with resectable NSCLC
- description
- 1 (one) 250mg beta-glucan capsule 3 times a day for 10 to 20 days
- interventionNames
- Dietary Supplement: beta-glucan
Primary outcomes (2)
- measure
- blood specimens will be obtained to examine the ability of beta-glucan to prime neutrophils complement receptor 3 (CR3) and test the cytotoxicity of the primed neutrophils.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
AIM 2: Inclusion Criteria: * suspected or definitive diagnosis of non-small cell lung cancer (NSCLC) * treatment naive or no treatment within 6 months prior to enrollment * able to swallow pills * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 3 * absolute neutrophil count (ANC) at least 1500/microl * able to understand and willing to sign a written informed consent document Exclusion Criteria: * history of hypersensitivity reactions attributed to beta-glucan * currently receiving continuous corticosteroids or other ongoing immunosuppressive therapy * presence of an uncontrolled intercurrent illness including but not limited to: ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements AIM 3: Inclusion Criteria: * resectable non-small cell lung cancer (NSCLC), as determined by a thoracic surgeon * treatment naive * able to swallow pills * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 * must be an operative candidate * absolute neutrophil count (ANC) at least 1500/microl * able to understand and willing to sign a written informed consent document Exclusion Criteria: * history of hypersensitivity reactions attributed to beta-glucan * currently receiving continuous corticosteroids or other ongoing immunosuppressive therapy * presence of an uncontrolled intercurrent illness including but not limited to: ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
References
Publications (0)
Data not yet available
No reference posted for this study.